LGALS3 and cardiovascular disorder: In the last few years, several studies have focused their attention on the role of galectin-3 in cardiovascular disease, especially as a reliable biomarker of ECM turnover in HF patients [12,18,30] that correlated with the adverse outcome in HF [7,12].